Published in J Nucl Med on January 15, 2010
Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging (2011) 1.50
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology (2013) 1.23
Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol (2014) 0.91
Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Res (2014) 0.79
Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. Biomaterials (2015) 0.77
Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys (2015) 0.75
Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma (2014) 0.75
A review of 3D image-based dosimetry, technical considerations and emerging perspectives in (90)Y microsphere therapy. J Diagn Imaging Ther (2015) 0.75
Renal dosimetry: ready for biological effective dose? Cancer Biother Radiopharm (2010) 2.24
Physical models and dose factors for use in internal dose assessment. Health Phys (2003) 1.85
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med (2007) 1.81
MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med (2002) 1.24
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm (2003) 1.17
MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med (2003) 1.09
Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. J Nucl Med (2006) 1.01
Radionuclides in marine fishes and birds from Amchitka and Kiska Islands in the Aleutians: establishing a baseline. Health Phys (2007) 0.99
Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med (2013) 0.96
Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest (2002) 0.90
Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med (2007) 0.88
RADAR commentary: Evolution and current status of dosimetry in nuclear medicine. J Nucl Med (2011) 0.86
Radiometals as payloads for radioimmunotherapy for lymphoma. Clin Lymphoma (2004) 0.84
Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity. J Nucl Med (2002) 0.83
Rapid MCNP simulation of DNA double strand break (DSB) relative biological effectiveness (RBE) for photons, neutrons, and light ions. Phys Med Biol (2015) 0.82
Comparison of point, line and volume dose calculations for exposure to nuclear medicine therapy patients. Health Phys (2011) 0.80
Numerical assessment of radiation binary targeted therapy for HER-2 positive breast cancers: advanced calculations and radiation dosimetry. Phys Med Biol (2007) 0.79
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest (2003) 0.79
Medical imaging: the challenges of radiation risk assessment. J Nucl Med (2014) 0.78
Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions. Phys Med Biol (2006) 0.78
Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. Cancer Biother Radiopharm (2002) 0.75
Blood-based red marrow dosimetry: where's the beef? J Nucl Med (2005) 0.75
Total-body and red marrow dose estimates. J Nucl Med (2003) 0.75
Renal dosimetry: ready for BED? Response to the Italian researchers. Cancer Biother Radiopharm (2011) 0.75
Renal dosimetry: ready for biological equivalent dose? Response to medical internal radiation dose and European association of nuclear medicine committee letters. Cancer Biother Radiopharm (2010) 0.75
Released nuclear medicine patients, security checkpoints, and the NRC. J Nucl Med (2008) 0.75
New tool for nuclear medicine patient release calculations. J Nucl Med (2009) 0.75
Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J Nucl Med (2017) 0.75
NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary. J Nucl Med (2004) 0.75
MCNP6 model of the University of Washington clinical neutron therapy system (CNTS). Phys Med Biol (2016) 0.75
Physics applications in nuclear medicine: 2007. J Nucl Med (2008) 0.75
MCNP5 evaluation of dose dissipation in tissue-like media exposed to low-energy monoenergetic X-ray microbeam. Radiat Environ Biophys (2005) 0.75
Rhodium self-powered neutron detector as a suitable on-line thermal neutron flux monitor in BNCT treatments. Med Phys (2011) 0.75
Physics in nuclear medicine: a year of tangible progress. J Nucl Med (2003) 0.75
Intravascular brachytherapy to prevent restenosis: dosimetric considerations. Cell Mol Biol (Noisy-le-grand) (2002) 0.75
Radiation Dose and Hazard Assessment of Potential Contamination Events During Use of 223Ra Dichloride in Radionuclide Therapy. Health Phys (2015) 0.75
DNA double strand break (DSB) induction and cell survival in iodine-enhanced computed tomography (CT). Phys Med Biol (2017) 0.75
Physics applications in nuclear medicine: carpe photon. J Nucl Med (2007) 0.75
Computational assessment of improved cell-kill by gadolinium-supplemented boron neutron capture therapy. Phys Med Biol (2003) 0.75